News
VALBIOTIS SA: Valbiotis announces completion of recruitment for the Cardio-Liver clinical study conducted with TOTUM•448 for metabolic liver diseases (MASLD)
Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintained preferential subscription rights for a gross amount of nearly €6.9 million, secured by subscription commitments of 75
VALBIOTIS SA: Valbiotis to launch ValbiotisPRO® Cardio-circulation on 2 June
VALBIOTIS SA: Strong Start to the Year in Line with the Company Roadmap: Expanding Sales Network, New Product Launches, & Growth in Pharmacy and Online Sales
VALBIOTIS SA: Valbiotis® strengthens its foothold in pharmacies with two strategic partnerships
VALBIOTIS SA: In anticipation of a change in regulations, Valbiotis® offers a scientifically proven alternative to red yeast rice for cholesterol management
VALBIOTIS SA: Valbiotis unveils its annual financial statements and confirms its strategic and financial goals
GenSight Biologics Announces Five-Year Efficacy and Safety Results for LUMEVOQ® Gene Therapy at the Conclusion of the REFLECT Study
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211039390/en/
Evolution of Visual Acuity in the REFLECT Phase III
VALBIOTIS SA: Valbiotis to launch its solution for the prevention of metabolic diseases, Valbiotis®PRO Metabolic Health (Totum•63), on February 3rd
VALBIOTIS SA: Valbiotis unveils its strategic and financial goals for 2030
VALBIOTIS SA: Valbiotis announces the major success of the phase II/III HEART II clinical study on LIPIDRIVE
Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking
Sensorion Reports 2025 Half-Year Results, Provides Corporate Update and Announces Availability of Half-Year Report
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Sensorion Announces Its Participation In Upcoming Investor Conferences
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Reports Cash Position as of June 30, 2025
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss